After launching a Bitcoin exchange-traded fund in Canada, Fidelity has now shifted its focus towards Metaverse-based ETFs in the USA.

PRESS RELEASE. LetsExchange.io, an instant cryptocurrency exchange platform, reports the tremendous growth it has achieved since its launch in early 2021. In March 2021, the platform had 6,000 active users from 20 countries. At the time, users could swap 200 digital coins and tokens, accounting for more than 40,000 crypto pairs. The figures in December […]

TOKYO, Jan 28, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022. CEO Naito represented pharmaceutical companies and highlighted the achievements of NTDs elimination activities by the industry and successes achieved by multi-sectoral partnerships. He also expressed Eisai's continued support for the elimination of NTDs towards the achievement of NTD road map 2021-2030 launched by the World Health Organization (WHO) last year. The 10th anniversary event aimed to recognize a decade of progress since the London Declaration, to confirm the strong commitment of stakeholders to continue the efforts for NTDs, and to strengthen endorsements from stakeholders to the Kigali Declaration on NTDs, the successor of the London Declaration which will be unveiled at the Commonwealth Heads of Government Meeting (CHOGM) scheduled for June 2022 in Kigali, the capital of the Republic of Rwanda.

Tremendous achievements have been made through public-private partnership since the launch of the London Declaration to 2020. The pharma industry has contributed to the elimination of NTDs via supply of medicines which resulted in donation of 13 billion high-quality treatments. Forty-three countries have eliminated at least one NTD and 600 million people no longer require interventions against NTDs. Despite such progress, more than 1.7 billion people remain threatened by NTDs.

In the event, CEO Haruo Naito said, "Our initiatives toward NTDs elimination are rooted in the pharmaceutical company's fundamental mission to deliver medicines to those who need them to treat illness and save lives. While R&D for NTDs treatments have become more active after the London Declaration, establishment of agile and flexible regulatory approval system as well as expansion of funding which leverages public-private partnership will be required to accelerate further innovations. Utilization of digital technologies such as remote medicine will help ensure delivery of and access to healthcare service under the vulnerable social infrastructure."

Under the London Declaration, Eisai has been manufacturing and supplying diethylcarbamazine (DEC) tablets, one of the lymphatic filariasis (LF) treatments, free of charge to the WHO for the elimination of LF. To date, 2.05 billion DEC tablets manufactured at Eisai's Vizag Plant in India have been supplied to 29 countries (as of January 2022). Although LF has been eliminated in 17 countries and the number of infected people has declined by 74% since 2000, 860 million people worldwide are still exposed to the risk of infection. Eisai is committed to providing DEC tablets for free to endemic countries that need DEC until LF is eliminated in these countries. In addition to the supply of DEC tablets, Eisai is working on various initiatives such as support for the mass drug administrations (MDA), disease awareness and improvements in sanitation.

Furthermore, Eisai is proactively engaged in development of new treatments for NTDs through partnerships with global research organizations. Utilizing the funding from the Global Health Innovative Technology Fund (GHIT Fund) and others, Eisai is conducting joint development of new treatments such as a new treatment for LF in collaboration with the Liverpool School of Tropical Medicine and the University of Liverpool as well as treatments for mycetoma and leishmaniasis in collaboration with the Drugs for Neglected Diseases initiative (DNDi).

Eisai commits to the Kigali Declaration and strengthens collaborations with global partners to tackle NTDs towards the achievement of NTD road map 2021-2030.

Based on human health care (hhc) philosophy, Eisai seeks to contribute to the health and welfare of people in developing and emerging countries. Once they recover their health, they can resume productive activities, which will in turn contribute to economic development and expansion of the middle-income class. Eisai considers this to be a long-term investment in creating the markets for the future. Eisai is actively engaged in leveraging partnerships with governments, international organizations, academia, and non-profit private sector organizations to accelerate the development of new treatments for infectious diseases including NTDs and facilitate initiatives to improve access to medicine such as support for MDAs and disease awareness activities. Through these initiatives, Eisai seeks to further contribute to patients and their families worldwide and increase the benefits that health care provides.

About Neglected Tropic Diseases (NTDs)

Neglected Tropic Diseases (NTDs) include 20 diseases that the WHO identifies as tropical diseases which human race must overcome. More than 1.7 billion people living in the poorest and most marginalized communities worldwide are exposed to the risk of NTDs infection. The spread of NTDs is mainly caused by poor hygienic conditions associated with poverty. Infections from these diseases may result in serious physical impairment and this often results in normal economic and social activities becoming highly challenging to the individual. In the worst cases, NTDs may also result in death. The prevalence of NTDs is a stumbling block to economic growth for developing and emerging countries and represents a serious issue for these regions.
The following 20 NTDs have been designated by WHO for control or elimination: dengue and chikungunya, rabies, trachoma, buruli ulcer, yaws (endemic treponematoses], leprosy (Hansen's disease], Chagas disease, human African trypanosomiasis (sleeping sickness], leishmaniasis, taeniasis / cysticercosis, dracunculiasis (guinea-worm disease), echinococcosis, food-borne trematodiases, lymphatic filariasis, onchocerciasis (river blindness], schistosomiasis, soil-transmitted helminthiases, mycetoma, scabies and other ectoparasites, and snakebite envenoming.

About London Declaration on Neglected Tropical Diseases

On January 30, 2012, the CEOs of 13 pharmaceutical companies*, the Bill & Melinda Gates Foundation, WHO, the U.S. Agency for International Development (USAID), the U.K. Department for International Development (DFID), the World Bank, and officials from NTD-endemic countries gathered in London to pledge their support for a coordinated effort to combat 10 NTDs**. The London Declaration represents the largest international public-private partnership in the field of global health to date, and unlike past approaches undertaken by an individual organization or for a single disease, the group has committed itself to working collaboratively in an effort to comprehensively tackle issues pertaining to drug supply, distribution, development, and implementation programs as it seeks to more effectively combat NTDs.

Commemorating the London Declaration, January 30 has been designated as the World NTD Day since 2020 and campaigns are held worldwide to light up the iconic landmarks and monuments in orange and purple, the symbol colors of NTDs. Eisai is sponsoring the light up of Tokyo Tower to raise disease awareness and disseminate the importance of eliminating NTDs.

* Abbvie, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, GlaxonSmithKline, Gilead, Johnson & Johnson, Merck (Merck KGaA: Germany), Merck Sharp & Dhome, Novartis, Pfizer, Sanofi
** Guinea worm disease, lymphatic filariasis, blinding trachoma, sleeping sickness (human African trypanosomiasis], leprosy, soil-transmitted helminthes, schistosomiasis, river blindness, Chagas disease, and visceral leishmaniasis

About Kigali Declaration on Neglected Tropical Diseases

As the successor of the London Declaration on NTDs launched in 2012, the Kigali Declaration represents a collective commitment from stakeholders to fight against NTDs. With the endorsements from stakeholders being initiated at the online event entitled "100% COMMITTED to End NTDs", a campaign to commemorate the 10th year anniversary of the London Declaration held on January 27, 2022, the Kigali Declaration will be unveiled at the Commonwealth Heads of Government Meeting (CHOGM) scheduled for June 2022 in Kigali, the capital of the Republic of Rwanda. To achieve the WHO's NTD roadmap 2021-2030, the Kigali Declaration aims to tackle NTDs comprehensively and sustainably by sustaining a multisectoral and multidisciplinary approach through public-private partnership, strengthening country ownership including establishment of local health system and domestic financing, accelerating research and development of treatments and diagnostics for NTDs and ensuring equitable access to these NTDs related products and services.

About Lymphatic Filariasis

Lymphatic filariasis (LF) is an NTD transmitted to humans via carrier mosquitoes. LF causes lymphatic dysfunction and can lead to the swelling of body parts such as legs, and cause severe pain, permanent disability and social stigma associated with disfiguring visible manifestations. As a result, patients suffer mental, social and financial losses. It is estimated that 860 million people worldwide, mainly those in developing countries, are exposed to the risk of LF. Elimination of LF is possible by stopping the spread of the infection through MDAs of three types of LF treatments including DEC tablets.

About Eisai's Commitment to Improving Global Access to Medicines including LF Elimination Program

In line with its hhc philosophy, Eisai is committed to improving global access to medicines over the medium-to-long term through partnership strategies that involve working with governments, international organizations, private entities and non-profit organizations.

In November 2010, Eisai agreed to supply a total of 2.2 billion DEC tablets to the WHO free of charge by 2020, as there was a global shortage of high-quality DEC tablets for use in MDAs. In 2012, Eisai became the only Japanese company to participate in the London Declaration, a coordinated effort to eliminate 10 NTDs and the largest public-private partnership of its kind in the field of global health. At the London Declaration's fifth anniversary event held in April 2017, Eisai announced its plan to supply DEC tablets continuously beyond 2020, until LF is eliminated in all endemic countries where DEC tablets are needed.

Eisai has supplied 2.05 billion tablets to 29 countries through the WHO's elimination program (as of January 2022). Furthermore, in order to support the smooth implementation of the WHO's MDA programs, Eisai is engaging in initiatives to raise public awareness of LF in endemic countries. Staff members of Eisai Group cooperate with the relevant representatives in endemic countries to eliminate LF as early as possible.

In addition to the above-mentioned initiatives, Eisai is moving ahead with new drug development projects targeting malaria and NTDs such as mycetoma and LF, based on partnerships with international non-profit organizations such as the Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV), as well as research organizations such as Liverpool School of Tropical Medicine, University of Kentucky, and the Broad Institute (please refer to the table above).

Furthermore, Eisai co-established the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public-private partnership to advance development of new health technologies for the developing world, is a member of the World Intellectual Property Organization (WIPO) Re:Search Consortium, an international joint enterprise for the development of treatments for NTDs, malaria and tuberculosis led by WIPO, is a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, and is participating in the Access Accelerated initiative to promote prevention and treatment of non-communicable diseases.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022.

HONG KONG, Jan 28, 2022 - (ACN Newswire) - An annual ceremony of Europe Gaming Awards by SIGMA took place at the Hilton Convention Centre, St. Julian's Malta. True Flip was nominated and recognized as the winner in the category Best Crypto Gaming Platform of the Year.

Both the judges and workers of the iGaming industry took part in the voting for the winner. The decision was made in the ratio of 70% the decision of the judges and 30% free voting on the SIGMA website.

This is the second award in one year for the TrueFlip brand - earlier this year TrueFlip was also recognized as Best Casino 2020 by AskGamblers. And even though the contenders were strong and also worth winning, True Flip was chosen Best of the Best again.

The team are proud to be part of this honor as well. Thanks to all who also invested in this success: TruePartners team, their partners, colleagues, clients. This event inspires us all to perform new feats.

TruePartners is an affiliate program, offering top converting brands in a broad geo spread. Generous bonuses, memorable design, and a player-centric retention system - this is what players get when becoming their partner. Among their brands are:

- TrueFlip.io
- TrueFlip.com
- Emojino.com
- LuckyNova.com

SIGMA provides premier networking opportunities and rewards leading players in the Gaming industry in a celebration of achievement. As well as shining a spotlight on some of the most intriguing and creative projects to change the face of the Gaming sector, the glitzy event also features an art auction, with all proceeds going to the SiGMA Foundation for a variety of charitable projects.

Media Contact
Brand: True Flip
Contact: Karina, PR manager
E-Mail: [email protected]
Website: https://truepartners.io/
Twitter: https://twitter.com/TrueFlipLoto

SOURCE: True Flip

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comAn annual ceremony of Europe Gaming Awards by SIGMA took place at the Hilton Convention Centre, St. Julian's Malta. True Flip was nominated and recognized as the winner in the category Best Crypto Gaming Platform of the Year.

The key to Bitcoin lies in the keys — and scaling based upon the understanding of current shortcomings and where improvements are needed.

Lost Recipes is out now on Meta Quest, but does it find the right mix of ingredients or all go up in flames? Here's our full review,

Wanderer is a hugely ambitious VR game that somehow achieves almost everything it sets out to accomplish. Our full review is here.

WonderHero is a blockchain NFT (non-fungible token) play to earn mobile game. The game is a turn-based RPG mobile game for iOS and Android where players collect Heroes, enter RPG combat and play to earn tokens in a fantasy world. You can play this game on just about any kind of mobile hardware! Built on [...]

The post WonderHero: An Anime-Styled Play to Earn Mobile RPG Launches on Polygon appeared first on Blockonomi.

Bern, Switzerland, Jan 27, 2022 - (ACN Newswire) - Cake Monster, a new decentralized finance (DeFi) protocol on the Binance Smart Chain (BSC), has announced a revolutionary supply burn for its token. From the onset, the team at Cake Monster has defined themselves as economic innovators. The economic and innovative model of the project combines a hyper-deflationary native asset ($MONSTA) with the acquisition of a non-correlated reserve asset ($CAKE). After approximately seven months, the protocol continues to put proof to the theory and is working beautifully.

The reserve is generated from a small transaction and proof of life tax (once every fifty days.) This ensures the continual and fair hyper-deflation of the total $MONSTA supply. The reserve is growing fast, with average monthly APYs well over 500% and over 188K $CAKE already in the vault. Over TWENTY percent (20%) of the total supply has been burned, amounting to over two billion $MONSTA tokens. This is an extraordinary achievement for a new protocol in the current market in such a small amount of time.

The Monster Supply Burn

With just under a year and a half to go until the end of the first cycle, the ongoing hyper-deflation (token supply burn) seems likely to make things very hot, driving the price of $MONSTA up as the supply shrinks. This, in turn, will increase the growth rate of the reserve and further increase demand for $MONSTA, potentially a volcanically virtuous cycle for token holders.

However, the platform does not stop there as the supply is also elastic. Once the first cycle is complete and the reserve contents are distributed to $MONSTA holders, a new cycle is triggered, and previous cycle holders will be reissued their $MONSTA. The re-issuance will be in proportion to their percentage of holdings at the end of the previous cycle. The heart of the protocol beats again; the hyper-deflation and reserve growth begin anew with remaining liquidity from cycle one added to the news cycle.

The Cake Monster platform is replete with incentives to earn, explore and have fun. Already deployed are; Crumbs, Kitchen Making, Cashout of inactive accounts, Diamond Claw NFTs, and the Monsta Party NFT and P2E platform (first to be launched and generated while in outer space... the video is extraordinary.)

About the $MONSTA Token

The monster token is a BEP-20 compliant token used within the Cake Monster ecosystem. The initial supply of the token is 10 billion. However, as a result of the monster burn, the final supply will be 1 million (0.1%) of the initial token supply. For the token distribution, 30% of the tokens will be utilized for community engagement, marketing, and airdrop, 10% for the team, 50% presale, and 10% for public sale.

Innovative Features of the Monster Ecosystem

- Single-sided $MONSTA staking
Once deployed, $MONSTA holders will be rewarded for their commitment, which may positively affect the market and growth rate of the reserve. The potential for centralized exchange listing is also increased due to simple technical solutions to the transaction tax being possible.

- Lottery
More than one lottery is under development but the first to be released is something the team dubbed "Eternal CAKE."

The Eternal CAKE lottery will enable active diamond claw NFT holders to mint a lottery ticket. The numbers will be drawn every three days. If a player wins, they will be able to claim their prize. If nobody wins, or the winner doesn't claim their prize, the $CAKE is added back to the pot for the next prize draw. This means the opportunity for some potentially juicy and large jackpots to be won.

Once you have minted (or purchased later from a marketplace) a lottery ticket, it never expires. In other words, it provides the owner with ongoing access to all future Eternal CAKE lottery draws.

- Rob-a-Monsta
This new addition to the Monsta Party NFT platform is a protocol feature called "Rob A Monsta" (RAM). It is a P2E (play 2 earn) game that will reward active Monsta Party players at the expense of inactive players.

All-Party Monstas that have ever been fed by their owner continually accrue $MONSTA dividends, even if never fed again. However, active players (those feeding their Party Monstas) will be able to claim any pending $MONSTA dividends for Party Monstas not being fed by initiating a "robbery."

- Multi-asset vault
After a recent vote of community members, which returned an overwhelmingly positive result in favor, a new reserve asset (BNB) will be added to the protocol, making it multi-asset. This is expected to provide significant additional resiliency and further collaboration and community growth opportunities.

About Cake Monster

Cake Monster ($MONSTA) offers a multitude of great features aimed at building a flexible, multifaceted, and automated dividend yield and reward system for participants without compromising the sustainability or security of the protocol ecosystem, and combines this with smart design, creativity, and organic growth, resulting in a very vibrant and engaged community.

Cake Monster may look like a meme at first glance, but behind the stunning artwork and fun, whimsical nature is an economic model with significant and powerful innovation. It has attracted many knowledgeable minds and a passionate and engaged community. Innovation within the project is rapidly accelerating, with incoming developments and deployments representing only a small part of what is to come. An incredibly comprehensive and efficient PR and marketing campaign strategy has been developed to maximize awareness, growth potential, discussion, education, and utility of the core protocol and all future deployments. With these building blocks and ambition to match, this project is worthy of attention and deep analysis.

About Cake Monster

Cake Monster ($MONSTA), a DeFi protocol on Binance Smart chain, offers unique features focused on developing a flexible, multifaceted, and automated dividend yield and reward system for participants. It's the first protocol to design an increasing Gravity Vault CAKE Reserve that opens up to all $MONSTA holders and rewards them with $CAKE.

For more information, visit
Website: https://cake.monster/
Twitter: https://twitter.com/MonstaPartyNFTs
Telegram: https://t.me/cakemnstr
Reddit: https://www.reddit.com/r/CAKEMONSTER/
Medium: https://cakemonster.medium.com/

Media Queries
Byron James, Cake Monster Media Office
Email: [email protected]r

SOURCE: Cake Monster

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comCake Monster, a new decentralized finance (DeFi) protocol on the Binance Smart Chain (BSC), has announced a revolutionary supply burn for its token.

By being detail oriented and preserving the critical properties of Bitcoin, Lightning enables rapid expansion of the network's usage.

Jones & Bartlett Learning awarded nine Book of the Year Awards by the American Journal of Nursing for excellence in nursing and health care.

(PRWeb January 26, 2022)

Read the full story at https://www.prweb.com/releases/jones_bartlett_learning_awarded_nine_prestigious_american_journal_of_nursing_awards_places_for_covid_19_interactive_case_studies_in_the_digital_products_category/prweb18454753.htm

United Esports and the Dfinity Foundation have created a blockchain game development contest with a $10 million prize pool.